Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01873833|
Recruitment Status : Active, not recruiting
First Posted : June 10, 2013
Last Update Posted : May 14, 2019
|Condition or disease||Intervention/treatment||Phase|
|HER2-positive Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer||Drug: capecitabine Drug: cyclophosphamide Drug: lapatinib ditosylate Biological: trastuzumab Other: laboratory biomarker analysis||Phase 2|
I. To estimate the progression free survival (PFS).
I. To evaluate the overall response rate (ORR).
II. To evaluate the clinical benefit rate (CBR; complete response, partial response, and stable disease for >= 24 weeks).
III. To estimate the overall survival (OS).
IV. To assess the safety and tolerability.
Patients receive capecitabine orally (PO) once daily (QD), cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab intravenously (IV) on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen|
|Actual Study Start Date :||July 29, 2013|
|Estimated Primary Completion Date :||July 27, 2020|
|Estimated Study Completion Date :||July 27, 2021|
Experimental: Treatment (chemotherapy, lapatinib ditosylate, trastuzumab)
Patients receive capecitabine PO QD, cyclophosphamide PO QD, and lapatinib ditosylate PO QD on days 1-21 and trastuzumab IV on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Drug: lapatinib ditosylate
Other: laboratory biomarker analysis
- PFS [ Time Frame: From the date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause, assessed up to 1 year ]One-sided one-sample logrank test will be used to evaluate the improvement in PFS compared to the reported historical PFS rate.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01873833
|United States, California|
|USC Norris Comprehensive Cancer Center|
|Los Angeles, California, United States, 90033|
|Principal Investigator:||Darcy V Spicer, MD||University of Southern California|